Coenzyme Q 9 (CoQ 9 ) in human plasma may originate as a product of incomplete CoQ 10 biosynthesis or from the diet. The estimated dietary CoQ 9 intake is 0 -1.3 mol/day, primarily from cereals and fats (1, 2 ) , but this is unreliable because many food items contain levels below the detection limit (1 ) .
Some methods for estimating human plasma CoQ 10 use CoQ 9 as an internal standard; thus, intraindividual variation in the concentration of endogenous CoQ 9 is a potential source of error.
We measured total CoQ 9 in human plasma, determined a reference interval, examined the biological variation, and documented the influence of CoQ 10 supplementation on plasma CoQ 9 concentrations.
Self-reportedly healthy volunteers (n ϭ 193; men/women, 82/113) were enrolled for determination of a reference interval for CoQ 9 . Mean age of participants was 45 years (range 18 -82). No participants reported taking CoQ 10 supplements.
Biological variation of CoQ 9 was determined in healthy adult male volunteers (n ϭ 10) who did not smoke and did not take vitamin or CoQ 10 supplements or medications in the 4 weeks before the study. Median age of the participants was 23.5 years (range 21-28). We took 7 blood samples from each participant in the morning after a 10-h overnight fast, at least 1 week apart, over a 2-month period.
We determined the effect of CoQ 10 supplementation on plasma CoQ 9 concentrations using the same 10 individuals. After baseline blood samples were taken, we administered a CoQ 10 supplement (Q-Gel, Tishcon USA) as a single, nominal 150-mg dose. A vegetarian breakfast and lunch were provided. We obtained a 2nd blood sample 6 h after administration of the supplement.
The plasma CoQ 9 and CoQ 10 assay, adapted from Tang et al. (3 ) , measured total CoQ 9 and CoQ 10 simultaneously. We measured total cholesterol and direct LDL-cholesterol on all samples, using enzymatic methods (Aeroset, Abbott Laboratories), with coefficients of variation (CVs) of 1.6% and 1.2%, respectively.
Blood samples were collected in lithium heparin, centrifuged within 1 h of collection, and plasma was stored protected from light: at Ϫ30°C until analysis (maximum storage time, 112 days) for the reference interval study; and at Ϫ80°C until analysis (maximum storage time, 150 days) for the biological variation and effect of CoQ 10 supplementation on plasma total CoQ 9 concentration studies. These studies were approved by the Canterbury Ethics Committee, Christchurch, New Zealand, and written informed consent was obtained from all participants.
Statistical analysis was carried out using SigmaStat and SPSS software.
Nonparametric statistics were used to determine the reference interval, and outliers were included in the analysis. Inter-and intraindividual variations were reported as CVs, correlation as the Pearson correlation coefficient, and comparisons by the Mann-Whitney rank-sum test. Statistical significance was inferred when P Ͻ0.05.
There was no significant difference in total CoQ 9 between males and females ( Table 1) .
CoQ 9 and CoQ 10 were significantly correlated (r ϭ ϩ0.577; P Ͻ0.001) in the reference cohort, suggesting that CoQ 9 could be made during CoQ 10 biosynthesis by omission of 1 isoprenoid unit. However, the observed correlation was also consistent with a hypothesis that CoQ 9 is a metabolite of CoQ 10 catabolism.
The intra-and interindividual variations in CoQ 9 were 20.9% and 35.5%, respectively. The index of individuality was 0.6 for CoQ 9 , calculated as within-subject variation/between-subject variation, whereas that for CoQ 10 was 0.4 (4 ) .
Plasma CoQ 9 increased after supplementation with CoQ 10 , with the median (2.5-97.5 percentiles) CoQ 9 concentration at baseline and after supplementation at 17.17 (9.23-36.81) and 26.94 (14.49 -39.55) nmol/L, respectively (P ϭ 0.052). The mean (SD) concentration of CoQ 9 ingested with the CoQ 10 supplements was 2.71 (0.99 g; n ϭ 6). The mean (SD) CoQ 9 concentration of the vegetarian breakfast was approximately 134 (63 g) (1, 2 ) . This increase in plasma Table 1 . The median (reference interval a ) for total CoQ 9 , total CoQ 10 , the CoQ 9 to CoQ 10 ratio, the CoQ 9 to total cholesterol ratio, and the CoQ 9 to LDL-cholesterol ratio. Our confirmation that CoQ 9 is a normal constituent of human plasma make it less than ideal for use as an internal standard, leading to underestimation of CoQ 10 by 1% to 7%. This complicates the CoQ 10 assay design and calls for further investigation.
The authors acknowledge Endolab for collaboration in the reference interval studies, Tishcon for donation of the Q-Gel ® CoQ 10 supplement, and the National Heart Foundation of New Zealand for funding. 1 ) . We fully agree with their reservations on the use of commercial assays by inexperienced laboratories and their point that patient management decisions should not be based on a single measurement of the ratio of aldosterone to plasma renin activity (ARR). We would like to reinforce this point by demonstrating the important influence of analytical variation on ARR measurement results.
Analytical Variation in Plasma Renin
Plasma renin activity (PRA) is evaluated as the difference in angiotensin I production by the enzyme at 37°C and endogenous angiotensin I, estimated by a determination of angiotensin I at 4°C. Therefore the CV of the assay is determined by the variations of the measurements at 37°C and 4°C.
To evaluate the impact of these assay variations on the ratio results, we performed 5 PRA determinations during a 5-week period on 2 samples with activities of ϳ0.6 and ϳ0.7 g/ L/h. The samples were divided into aliquots and kept at Ϫ80°C until analysis. Using the RENCTK reagent set (Diasorin) according to the manufacturer's instructions, 4 welltrained and experienced technicians (with an average work experience of 26.8 years) performed the tests along with routine PRA determinations. The results are presented in Table 1 .
Given the effect of analytical variation on the mean values obtained and using the highest value possible at 37°C with the lowest value at 4°C and vice versa, PRA values would range from 0.44 to 0.81 g/L/h for sample 1 and from 0.58 to 0.89 g/ L/h for sample 2. If these values occurred in patients with slightly increased supine aldosterone (e.g., 200 ng/L), with an acceptable CV of 10% for aldosterone measurement, the ARR would range from 22 to 50 for patient 1 and from 20 to 38 for patient 2. Therefore, even with major differences in the criterion for a raised ARR (2 ), the width of the grey zone around the threshold value allows a patient result to be indiscriminately considered as "normal" or "pathologic" based on a single sample.
This approach, it may be argued, is purely analytical, and a slight degradation of angiotensin I over time could have had an important impact on the low values measured in this study. Moreover, endogenous angiotensin I concentrations are below the first quantifiable point of the curve and perhaps should not be reported. Nevertheless, many studies published on screening for primary aldosteronism either did not consider PRA analytical variation or underestimated it because activities in the samples used for estimating between-assay variation were much higher than 0.6 or 0.7 g/L/h, lead- 
